Home / Health / India's Dengue Vaccine Enters Final Test Phase
India's Dengue Vaccine Enters Final Test Phase
27 Feb
Summary
- Dengue vaccine candidate DengiAll is in Phase III trials with 10,000 volunteers.
- The vaccine aims for a single dose protecting against all four dengue virus types.
- If successful, DengiAll could be available in India by next year.
As dengue cases rise globally, an Indian vaccine candidate, DengiAll, has advanced to the final Phase III trial stage. Over 10,000 volunteers are participating in the study across India, with results anticipated later this year. Developed by Panacea Biotec over nearly 15 years, DengiAll seeks to be a single-dose vaccine effective against all four dengue virus serotypes.
Climate change is exacerbating dengue outbreaks by creating ideal conditions for Aedes mosquitoes. India alone has seen over one million cases since 2021. If the trials are favorable, DengiAll could be rolled out by next year, marking a significant step in combating the disease, especially for India and other lower-middle-income countries where no dengue vaccine is currently licensed.
